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CHAPTER 1 
NATURAL HISTORY AND MANAGEMENT OF MCNS 
 
INTRODUCTION 
Pancreatic mucinous cystic neoplasms (MCN) are rare mucin-producing cystic 
tumors. They are predominantly found, incidentally, in middle-aged women and 
usually located in the pancreatic body or tail. They are differentiated from other 
mucin producing neoplasms by the presence of ovarian-type stroma.1 They have 
been classified separately from intraductal papillary mucinous neoplasms (IPMNs) 
by the World Health Organization (WHO) since 19962 and the Armed Forces 
Institute of Pathology (AFIP) from 1997.3 The current management of MCN is 
defined by the consensus European,4 International Association of Pancreatology 
(IAP)5 and the American Association of Gastroenterology guidelines.6 However, 
the malignant potential of these lesions remains uncertain, with differing rates of 
malignant potential being described. Since the criteria for surgical resection differs 
between the current guidelines, we have performed a systematic review of the 
literature to better define the natural history and prognosis of these lesions and to 
inform recommendations for future management.  
 
METHODS 
We performed a systematic review of the literature using the PubMed, EMBASE 
and the Cochrane Library. The search was limited to studies published in the 
English language between 1970 and 2015. MeSH terms were decided by a 
consensus of the authors [Figure 1]. The search was restricted to title, abstract and 
keywords. Articles that described only outcomes for other cystic lesions of the 
pancreas or that included fewer than five patients with an MCN were excluded. 
Case reports, abstracts as well as reviews were also excluded. All references were 
screened for potentially relevant studies not identified in the initial literature search.  
The following variables were extracted for each report when available: age, gender, 
presence of ovarian-type stroma, associated symptoms, location, communication 
with main pancreatic duct, histology, survival, surgical complications and length of 
follow-up. Tumors with invasive carcinoma but not carcinoma in situ were 
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classified as malignant. 52 papers were included in the final analysis [Figure 1, 
Table 1].  
 
RESULTS 
MCNs mainly occur in women (female: male ratio 20:1) with a peak incidence in 
the 5th decade. They are usually located in the pancreatic body or tail (93 - 95%) 
and rarely communicate with the main pancreatic duct (0-33%).7-11 Studies suggest 
10-49% of surgically resected neoplastic cysts are MCNs.12,13  
1. Pathophysiology 
Pancreatic MCNs are defined pathologically as mucin-producing cysts that are 
surrounded by ovarian-type stroma (not found in other pancreatic neoplasms).14,15 
The origin of ovarian stroma is unknown, but it contains oestrogen and progesterone 
hormone receptors which appears to drive the tumour growth and may explain the 
predominance for these lesions to occur in women.16  
Resected MCNs are typically large solitary masses17 (average diameter: 7-10 cm, 
range: 2-36 cm, [Table 3]). Septations are common, leading to formation of 
multilocular cysts. Invasive carcinoma should be suspected if mural nodules or a 
solid component is present.17 
MCNs are lined by tall columnar mucin producing epithelial cells.14,15 The 
epithelium can be associated with low to high-grade dysplasia or invasive cancer 
(present in 0-34%) [Table 1]. Invasive cancer in MCN pathologically resembles 
pancreatic ductal adenocarcinoma (PDAC).18 Rates of associated malignancy in 
MCN are much lower than in other mucinous cystic lesions; main duct-IPMNs 
(35.7-100%) and branch duct-IPMNs (8.2-51%)19 suggesting MCNs may take 
longer to undergo malignant transformation or have lower malignant potential.   
Like PDAC, malignant transformation of MCNs is associated with mutations in 
KRAS and PIK3CA oncogenes, tumour suppressor genes TP53, DPC4/SMAD4, 
RNF43 and P16INK4A/CDKN2A and the disruption of the hedgehog and Wnt 
signalling pathway.20 Somatic mutations in PIK3CA occur frequently in MCN,21 
less commonly in IPMN22 and not at all in PDAC.23 In MCN and IPMN22 the 
mutation was only found in areas of high-grade dysplasia and coexisted with the 
KRASG12D mutation, suggesting that together they may trigger the final steps of 
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carcinogenesis. In advanced MCN, inactivation of TP53 may also contribute to 
malignant transformation.24  
2. Clinical presentation 
Many MCNs are discovered incidentally12,25,26 but some patients report mild or 
vague abdominal pain, abdominal heaviness or fullness, an abdominal mass, nausea 
or vomiting, back pain, recurrent pancreatitis or rarely jaundice [Figure 2, Table 
2].12,18,26-28  
Symptoms can be present for years, but being non-specific can lead to delays in 
diagnosis. Whether symptoms predict malignant transformation in MCN remains 
unclear,25 but it should be suspected in any MCN patient if weight loss or back pain 
is present.18,26 Invasive disease is more common in older patients.19 
3. Assessment and Diagnosis 
Serum tumor markers 
Serum tumor markers alone cannot be used to diagnose MCN or differentiate them 
from other cystic lesions, but they are potentially useful in differentiating malignant 
and benign cystic lesions as high levels of CEA and CA-19.9 are suggestive of 
malignant transformation.25,29-31  
Radiology 
The European cystic tumor guidelines recommend that a CT or MRCP is performed 
to diagnose and characterize all cystic lesions of the pancreas.4 International 
guidelines suggest cross-sectional imaging is only necessary once lesions reach 
10mm, if detected by another method.19 MRI is preferable for diagnosing and 
characterizing small lesions.4 Most MCNs are currently diagnosed at around 10mm 
in size, but this has fallen over time [Figure 2].4  
Imaging features predictive of malignant transformation32 include: cyst size ≥3cm 
(OR = 62), mural nodule (OR = 9.3), dilated main pancreatic duct ≥ 6 mm (OR = 
7.3) or peripheral eggshell calcification.32 Imaging features and final pathology 
often correlate poorly, so where uncertainty remains surgical resection is still 
recommended.33  
 
 
Endoscopic ultrasound (EUS) 
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Being a safe and well-tolerated procedure (adverse events: pancreatitis, bleeding, 
infection in <2%), EUS with fine needle aspiration (FNA) is often employed in 
the assessment and surveillance of cystic lesions of the pancreas,34,35 although its 
absolute utility in surgical decision-making continues to be debated.4,19,33,36  
Cyst fluid obtained at EUS-FNA can be immediately assessed for the “string-sign” 
which suggests a mucinous lesion.37 It is then typically sent for biochemical and 
cytological assessment. A raised carcinoembryonic antigen (CEA) (>192 ng/mL) 
and a low amylase are typical of an MCN.  
Obtaining sufficient fluid for cytological and biochemical assessment can be 
challenging in small cysts, especially when mucinous (as contents are viscous and 
difficult to aspirate).38 Current research strategies are therefore evaluating through 
the needle optical biopsy (Mauna Kea Technologies, Paris)39 protein and genetic 
markers 40,41 which can be performed on smaller samples. Research is ongoing to 
validate these novel techniques.  
4. Treatment 
Surveillance 
Current guidelines advocate surgery for the majority of patients with an MCN. 
However, in lesions <4cm, that are asymptomatic and without worrisome features, 
the rate of associated malignancy is just 0.03%.42 Therefore surveillance of small 
MCNs (<4cm) appears to be a safe strategy, but currently this is only advocated by 
the European guidelines. Mostly these lesions are diagnosed in young women, who 
will require long-term surveillance by MRI or EUS,4,19 6-monthly during the first 
year, then annually if stable, as long as they are fit for surgical resection. 
Surveillance is inconvenient, anxiety provoking and costly and in this group the 
risks of surgical resection and postoperative complications (chronic diabetes and 
pancreatic endocrine insufficiency) need to be balanced against continued 
surveillance.42  
Surgical management  
In MCNs <4cm and without worrisome features, organ-preserving pancreatic 
resection is recommended, including parenchyma sparing resections (middle 
pancreatectomy) and non-anatomic resections (excision, enucleation, 
uncinatectomy). In lesions >4cm or that have features suggestive of invasive 
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malignancy (mural nodules, peripheral egg-shell calcification), an oncological 
resection with lymphadenectomy is recommended.4,19  
MCNs are usually located in the body/tail of the pancreas and require a distal 
pancreatectomy26 which can be done without splecentomy if the suspicion of 
malignancy is low. Lesions in the body require an extended left resection. 
Postoperative mortality following these operations is almost zero, but morbidity 
remains significant (pancreatic fistula in 10-30%).43 
A middle pancreatectomy can be considered for small lesions in the body/neck but 
this is more challenging than a distal resection and postoperative complications are 
higher (fistula in 34%).33,44,45 Alternatively small tumors (<2cm) without malignant 
features can be managed by enuculation,18,46 but again rates of pancreatic fistula are 
increased (30-50%).46,47 Intraoperatively a pathologist uses a frozen section from 
the proximal margin, to assess the completeness of resection and if an oncological 
resection is required.4  
For MCNs occurring in the head, a pancreatico-duodenectomy (pylorus-preserving 
or Whipple) is performed.26 Postoperative mortality is 0-6% in high volume centres, 
but postoperative complications remain common (40-60%).48 
Laparoscopic resections have been performed in selected patients with benign 
MCNs49 but lower rates of postoperative complications were not seen.26 The utility 
of laparoscopic resections is malignant MCNs remains unclear. 
Oncology 
No conclusive data exists for neo-adjuvant or adjuvant therapy for malignant 
MCNs. Current treatment options have been extrapolated from the management of 
PDAC and invasive IPMN and typically include gemcitabine or fluorouracil.4 
Reports from small series of patients receiving adjuvant chemotherapy in invasive 
MCN have demonstrated a survival advantage.26 
Follow-up after resection 
Complete resection of a non-invasive MCN is curative, recurrence has not been 
reported,4 and further postoperative surveillance is therefore not required.17,18 
Invasive MCN should be followed-up like PDAC (regular CA19-9 and annual 
cross-sectional imaging).4 Whether this management of malignant MCN improves 
prognosis over a symptom based assessment alone remains unknown.19 
8 
 
5. Prognosis  
MCNs of <4cm have a low prevalence of malignant transformation.25 Non-invasive 
MCNs have an excellent prognosis,13 making resection prior to malignant 
transformation vital.4 Complete resection of a non-invasive MCN is curative19 
regardless of the degree of cellular atypia and five-year survival is 100% [Table 
4].13 Surgical series have reported that 0-34% of resected MCNs are associated with 
invasive cancer, however these series have included larger lesions with more 
features of concern.4 In lesions <4cm and without worrisome features, malignant 
transformation occurred in only 0.03%.50 Five-year survival in patients with 
invasive MCNs ranges from 0-75%.19,25  
 
DISCUSSION 
To date this is the largest systematic review of the natural history and prognosis of 
MCNs. These tumors represent about 20% of all resected pancreatic cystic tumours 
and occur almost exclusively in middle-aged women. Growth of these lesions and 
rates of malignant progression are thought to be driven by the hormones oestrogen 
and progesterone, their receptors are present in the ovarian-type stoma of MCNs 
and these lesions grow rapidly when concentrations of these hormones rise e.g. in 
pregnancy. MCNs are often asymptomatic at the time of diagnosis, typically being 
discovered during abdominal investigations performed for another reason. In 
symptomatic patients, the most common symptoms are abdominal or back pain.  
The accuracy of pre-operative investigations for diagnosing an MCN ranges from 
47-83% depending on the modality used and if it has been employed in combination 
with other tests.33,36,51,52 No substantial differences exist between CT, MRI or EUS 
for detecting features of concern associated with MCN and test selection is best 
decided based on trying to limit a patients exposure to ionising radiation and local 
expertise. For surveillance radiation-free investigations such as MRI or EUS should 
be used.4  
Historically surgical resection was advocated for all surgically fit patients with an 
MCN.19 However, these lesions are increasingly detected at an earlier stage [Figure 
2] and appear to be associated with much lower rates of malignancy than previously 
thought. The recent European consensus guidelines have advocated a less 
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aggressive management approach for these lesions in certain situations e.g. when 
<4cm in size and in the absence of features of concern.4 In indeterminate lesions or 
when the radiological features are inconclusive or contradictory the management is 
more challenging and surgical resection remains the safest approach, if there is 
sufficient clinical concern.  
Given that the majority of surgically resected MCNs are benign, especially if small 
in size, a “non-oncological resection” or parenchyma sparing resection is the 
preferred approach. Where any suspicion of malignant transformation remains, a 
radical resection is mandatory. For benign MCN no follow-up is needed after 
radical resection, as the risk for recurrence is absent. For lesions with invasive 
cancer, the 5-year survival rate is approximately 60% and regular surveillance is 
recommended.  
Although our review has included all recent published series of surgically resected 
MCN, a potential limitation is that many of the series report the findings of a single 
centre and contain relatively few patients. In addition, many old series did not 
define MCNs by the presence of ovarian-type stroma, so may have inadvertently 
included non-MCN lesions, which may explain the higher rates of malignancy and 
differences in associated features seen in these early series.8,53,54 Larger multicentre 
studies, with thorough radiological and pathological characterization of MCNs are 
needed to fully validate the findings of this review. 
 
CONCLUSION 
Our comprehensive systematic review supports emerging trends in the literature 
that MCNs are probably more indolent lesions than was previously thought. They 
have a low aggressive behavior, with exceptionally low rates of malignant 
transformation when less than 4cm in size, are asymptomatic and lack worrisome 
features on pre-operative imaging. Conservative management, particularly of small 
MCNs appears to be a reasonable strategy. This differs significantly from the 
natural history of small BD-IPMNs, supporting the need to differentiate mucinous 
cyst subtypes pre-operatively, where possible. These findings support the 
management of MCN advocated by the recent European Guidelines. 
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TABLES AND FIGURES 
 
Figure 1. Search flowchart of systematic literature review. MeSH terms were decided by 
a consensus of the authors and were restricted to the title, abstract and keywords. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mucinous cystic neoplasm (n=333) 
AND 
Surgery (n=945083) 
Pregnancy (n=728652) 
Oestrogen or oestradiol (n=118398) 
Endoscopy (n=269086) 
CT (n=316022) 
MRI (n=323073) 
Ultrasound / endoscopic ultrasound (n=165175) 
Chemotherapy (n=318221) 
Catheter ablation (n=24235) 
Prognosis (n=374965) 
Genetics (n=12025) 
Management (n=867139) 
Biological markers (n=171259) 
 
TOTAL: n =181 
 
    
 
n = 139  
 
Papers included: n=52 
 
  
 
Limited to English 
language, abstract, 
humans, 1970-current 
 
 
  
 
Ovid MEDLINE 1946-current and EMBASE 1947-current 
   
 
Excluded following title 
and abstract review:  87 
papers 
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Figure 2. Changes in features of surgically resected MCNs where all (or a proportion) of the 
lesions have been defined by the presence of ovarian type stroma 
A. Changes in reported size of MCNs over time 
 
 
B. Changes in reported rates of associated symptoms over time 
 
 
C. Changes in reported rates of associated invasive malignancy over time 
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Table 1. Patient demographics and rates of associated carcinoma in situ and invasive cancer 
in surgically resected case series of patients with MCNs. 
Author and year 
Ovarian 
stroma 
present % (n) 
N 
Average age in 
years (range) 
M:F 
CIS or invasive 
cancer % (n) 
Invasive cancer  
% (n) 
Studies where MCNs were defined by the presence of ovarian stroma 
Fukushima, 1997 7 90% (9) 10 49 (29-61) 0:10 40% (4) NR 
*Zamboni, 1999 8 86% (48) 56 48 (18-78) 0:56 39% (22) 29% (16) 
*Thompson, 1999 27 100% (130) 130 45 (20-95) 0:130 54% (70) NR 
Shimizu, 2002 9 100% (6) 6 53 (40–68) 0:6 33% (2) 0% (0) 
Hara, 2002 55 100 % (5) 5 54 (36–69) 0:5 40% (2) NR 
Izumo, 2003 10 100% (34) 34 44 (24–81) 0:34 12% (4) 3% (1) 
Kosmahl, 2004 11 100% (32) 32 47 (23-78) 0:32 44% (14) 34% (11) 
*Reddy, 2004 28 100% (56) 56 48 (17–78) 1:55 11% (6) 7% (4) 
Sawai, 2004 56 100% (8) 8 57 (33–80) 0:8 25% (2) NR 
Yeh, 200457 100% (7) 7 55 (NR) 0:7 14% (1) 14% (1) 
*Crippa, 2008 18 100% (163) 163 45 (16-82) 8:155 17% (28) 12% (19) 
*Crippa 2010 42 100% (168) 168 45 (16-82) 8:160 17% (29) 11% (19) 
*Yamao, 2011 17 100% (156) 156 48 (19-84) 3:153 17% (27) 4% (6) 
*Baker, 2012 58 100% (291) 291 NR 9:282 NR 13 (38) 
Park, 2014 25 100% (90) 90 48  (NR) 1:89 10% (9) 4% (4) 
Studies which used criteria other than presence of ovarian stroma when defining MCN 
^Compagno, 1978 1 NR 41 49 (20–82) 6:35 46% (29) NR 
^Warshaw, 1990 59 NR 42 
MCN: 59 (NR), 
MCA: 63 (NR) 
10:32 64% (27) NR 
Shyr, 1996 60 NR 10 48 (26–72) 2:8 80% (8) NR 
Sugiyama, 1997 61 NR 18 52 (22–65) 7:11 67% (12) NR 
Wilentz, 1999 62 NR 61 56 (NR) 18:43 48% (29) 33% (20) 
*^Le Borgne, 1999 63 NR 228 
MCN: 52 (20-80) 
MCA: 64 (29-89) 
80:148 34% (78) NR 
Scott, 2000 64 NR 13 53 (22–82) 3:10 77% (10) NR 
^Sarr, 2000  54 NR 84 
MCN: 48 (19–82) 
MCA: 64 (NR) 
14:70 NR 8.3% (7) 
Shima, 2000 65 NR 6 51 (37–74) 0:6 33% (2) NR 
Yamaguchi, 2000 66 NR 21 53 (NR) 3:18 52% (11) NR 
Fujino, 2001 67 NR 14 51 (36–71) 5:9 57% (8) NR 
Yeh, 2002 68 NR 12 45 (19–70) 5:7 67% (8) NR 
*Kim, 2003 69 NR 15 51 (NR) 2:13 0% (0) 0% (0) 
Spinelli, 2004 70 NR 19 NR NR 16% (3) NR 
Goh, 2005 71 44% (8) 18 43 (25–73) 1:17 17% (3) 6% (1) 
*Suzuki, 2004 72 
Present in 
42% (73) and 
indefinite in a 
further 37% 
179 (6 
cases not 
surgically 
resected) 
56 (19–74) 0:179 31% (53) NR 
Allen, 2006 73 NR 25 NR NR 24% (6) 12% (3) 
Theruvath, 2010 74 NR 32 49 (NR) 2:30 16% (5) NR 
* Includes patients from more than one centre. ^: Possibly includes some cases of IPMN as well as MCN. MCN: Mucinous 
Cystic Neoplasm, MCA: Mucinous Cyst adenocarcinoma, CIS: Carcinoma in Situ, NR: Not recorded. 
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Table 2. Clinical symptoms associated with resected MCNs where all (or a reported proportion) of lesions have been defined by the presence of ovarian-type stroma 
Author 
and year 
All MCNs: 
symptoms 
% (n) 
Benign 
MCN: 
symptoms 
% (n) 
MCA with 
invasion: 
symptoms 
% (n) 
Sympto
m 
duration 
Abdomina
l Pain / 
discomfort 
% (n) 
Back 
Pain 
% (n) 
Dyspepsia  
/ Reflux / 
PUD 
% (n) 
Abdo 
Mass 
% (n) 
AP 
% 
(n) 
DM 
% 
(n) 
N+
V % 
(n) 
Diarrhoea 
% (n) 
Constipation 
% (n) 
Weigh
t loss 
% (n) 
Lethargy 
% (n) 
Bleeding/ 
anaemia 
% (n) 
Jaundice 
% (n) 
Other % (n) 
Fukushima 
1997 7 
50% (3/6) 60% (3/5) 0% (0/1) NR 17% (1) 
17% 
(1) 
0% (0) 
17% 
(1) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% (0) 0% (0) 0% (0) 0% (0) NR 0% (0) 0% (0) 
Zamboni    
1999 8 
89% 
(50/56) 
85% 
(29/34) 
(exc CIS) 
95% 
(21/22) 
(inc CIS) 
NR 70% (39) 0% (0) 16% (9) 
7% 
(4) 
0% 
(0) 
0% 
(0) 
2% 
(1) 
0% (0) 2% (1) 
10% 
(6) 
0% (0) NR 0% (0) 0% (0) 
Thompson 
1999 27 
88% (114) NR NR 
Few 
days - 
34 years 
72% (94) 0% (0) 2% (3) 
43% 
(56) 
13% 
(17) 
4% 
(5) 
18% 
(23) 
5% (6) 0% (0) 7% (9) 0% (0) 5% (7) 
2% (3) 
(all 
MCA) 
Cholecystitis/
cholelithiasis 
12% (16) 
Hara            
2002 55 
80% (4) 
67% (2) 
(exc CIS) 
100% (2) 
(inc CIS) 
NR 60% (3) 
20% 
(1) 
0% (0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 
Izumo          
2003 10 
65% (22) NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR NR 
Reddy        
2004 28 
84% (47) NR NR NR 52% (29) 0% (0) 0% (0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
4% 
(24) 
0% (0) 0% (0) 
21% 
(12) 
0% (0) 0% (0) 2% (1) 0% (0) 
Sawai          
2004 56 
50% (4) NR NR NR 13% (1) 
13% 
(1) 
0% (0) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
13% 
(1) 
0% (0) 0% (0) 0% (0) 13% (1) 0% (0) 0% (0) 0% (0) 
Suzuki, 
2004 72 
44% (78) 36% (43) 57% (30) NR 25% (45) 0% (0) 0% (0) 
0% 
(0) 
4% 
(7) 
13% 
(23) 
0% 
(0) 
0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 
Hyperamylas
emia 2% (3), 
CLP 1% (2), 
CP 1% (1) 
Goh,  
2005 71 
72% (13) NR NR 
Mean: 9 
months 
72% (13)* 
72% 
(13)* 
0% (0) 
44% 
(8) 
6% 
(1) 
18% 
(3) 
0% 
(0) 
0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 
Crippa  
2008 18 
73% (118) 72% (97) 75% (21) 
Pain: 
Median 
12 
weeks 
(range: 
1-102) 
60% (98) 0% (0) 0% (0) 
12% 
(20) 
9% 
(15) 
0% 
(0) 
0% 
(0) 
0% (0) 0% (0) 
12% 
(19) 
10% 
(17) 
0% (0) 0% (0) 0% (0) 
Crippa 
2010 42 
73% (122) NR NR NR 62% (104) 0% (0) 0% (0) 
0% 
(0) 
6% 
(9) 
6%( 
9) 
0% 
(0) 
0% (0) 0% (0) 
16% 
(27) 
0% (0) 0% (0) 1% (1) 0% (0) 
Yamao 
2011 17 
49% (67) 46% (51) 48% (11) NR 0% (0) 0% (0) 0% (0) 
0% 
(0) 
6% 
(10) 
5% 
(7) 
0% 
(0) 
0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 
Hyperamylas
emia 1% (1) 
Park  
2014 25 
51% (46) 52% (42) 44% (4) NR 23% (21) 0% (0) 11% (10) 
12% 
(11) 
0% 
(0) 
0% 
(0) 
0% 
(0) 
0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 4% (4) 
*Abdominal and back pain symptoms recorded together, AP: Acute pancreatitis, CP: chronic pancreatitis, CLP: cystic lesion of the pancreas, MCN: Mucinous Cystic Neoplasm, MCA, Mucinous cyst adenocarcinoma, 
CIS: Carcinoma in Situ, DM: Diabetes Mellitus, N+V: Nausea and vomiting, PUD: Peptic ulcer disease, pts: patients, exc: excludes, inc: includes
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Table 3. Radiological features associated with benign and malignant MCNs where all (or a reported proportion) of lesions have been defined by the presence of ovarian type stroma 
NR: Not recorded, LGD: MCN with low grade dysplasia, IGD: MCN with intermediate grade dysplasia, HGD/CIS: MCN with high grade dysplasia / carcinoma in situ, NR: Nor reported, N/A: Not applicable, ^: Determined by 
pancreatography at ERCP preoperatively, 3 cases (60%) did have a pancreatic duct connection in the resected specimen  
 
 
Author 
and year 
All MCN Benign MCN (including CIS) MCA with invasive cancer 
 
Average 
size in 
cm 
(range) 
Head  
% (n) 
Body / tail  
% (n) 
Solid 
componen
t  % (n) 
Septations / 
multilocular 
cysts % (n) 
PD 
communicatio
n 
% (n) 
Average size in 
cm (range) 
Head  
% (n) 
Body / 
tail  
% (n) 
Solid 
componen
t  % (n) 
Septations / 
multilocular 
cysts % (n) 
Average 
size in cm 
(range) 
Hea
d  
% 
(n) 
Body / 
tail  
% (n) 
Solid 
componen
t  % (n) 
Septations / 
multilocular 
cysts % (n) 
Fukushim
a 1997 
7
 
7.1 
(2-20) 
0% (0) 100% (10) 20% (2) 20% (7) 33% (2/6) 
7.1 
(2-20) 
0% (0) 
100% 
(10) 
20% (2) 20% (7) 
7.1 
(2-20) 
0% 
(0) 
100% 
(10) 
20% (2) 20% (7) 
Zamboni    
1999
8
 
8.4 
(2-23) 
7% (4) 93% (52) 20% (11) 64% (35) 0% (0) 
LGD: 7 (2-23) 
IGD: 9.6 (3.5-18) 
HGD/CIS: 7.8 (5-
12) 
5% (2) 
95% 
(38) 
3% (1) 55% (22) 
9.8 
(3-18) 
13% 
(2) 
87% 
(13) 
67% (10) 87% (13) 
Thompson 
1999
27
 
10.6 
(1.5-30) 
6% (5) 94% (125) NR 99% (128) NR NR NR NR NR NR NR NR NR NR NR 
Shimizu      
2002
9
 
6.5 
(2–11) 
0% (0) 100% (6) NR 83% (5) 0% (0) 6.5 (2–11) 0% (0) 
100% 
(6) 
NR 83% (5) N/A N/A N/A N/A N/A 
Izumo          
2003 
10
 
8.4 
(2.5-25) 
0% (0) 100% (34) NR NR 17% (4/23) NR NR NR NR NR NR NR NR NR NR 
Reddy        
2004
28
 
5 
(0.6-35) 
7% (4) 93% (52) NR NR NR NR NR NR NR NR NR NR NR NR NR 
Kosmahl, 
2004 
11
 
9.8 
(2.7-23) 
6% (2) 94% (30) NR NR 0% (0) NR NR NR NR NR NR NR NR NR NR 
Crippa 
2010
42
 
4.9 
(0.8-15) 
3% (5) 97% (163) NR NR NR NR NR NR NR NR NR NR NR NR NR 
Hara            
2002
55
 
9.4 
(8–13) 
0% (0) 100% (5) 60% (3) 100% (5) 0% (0)^ 
8.7 (4.5-13) 
 
0% (0) 
100% 
(2) 
33% (1) 
100% (3) 
 
11 (8-13) 
0% 
(0) 
100% 
(2) 
100% (2) 100% (2) 
Sawai          
2004
56
 
4.9 
(4.0–7.5) 
0% (0) 100% (8) 25% (2) 88% (7) NR 
NR 
 
0% (6) 
 
100% 
(6) 
17% (1) NR 
NR 
 
0% 
(0) 
100% 
(2) 
50% (1) NR 
Suzuki, 
2004 
72
 
5.9 
(0.18-
23) 
19% 
(32) 
81% (125) 28% (48) NR 12% (22) 
5.4 
 
NR NR NR NR 
7.2 
 
NR NR NR NR 
Goh,  
2005 
71
 
9.1 
(3-18) 
0% (0) 100% (18) NR NR 0% (0) 
8.5 (NR) 
 
0% (0) 
100% 
(NR) 
27% (4) NR 
14.0 (NR) 
 
0% 
(0) 
100% 
(3) 
100% (3) NR 
Crippa  
2008
18
 
5.0 
(0.8-
15.0) 
3% (5) 97% (158) 15% (24) 38% (62) 0% (0) 4.5 (0.8-15) 
4% (5) 
 
96% 
(130) 
4% (6) 37% (50) 
8 (2-13) 
 
0% 
(0) 
100% 
(28) 
64% (18) 43% (12) 
Yamao 
2011
17
 
6.5 
(1-26) 
1% (1) 99% (155) 27% (42) NR 18% (25) 
6 (NR) 
 
1% (1) 
99% 
(128) 
22% (28) NR 9 (NR) 
0% 
(0) 
100% 
(27) 
52% (14) NR 
Park  
2014
25
 
6.4 
(NR) 
12% 
(11) 
88% (79) 10% (6) 56% (35) 5% (3) 6.6 (NR) 6% (5) 
94% 
(76) 
5% (3) 57% (33) 
5.5 (NR) 
 
11% 
(1) 
89% 
(8) 
60% (3) 40% (2) 
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Table 4. Survival and recurrence in benign and malignant MCNs where all (or a reported proportion) of lesions have been defined by the presence of ovarian type stroma 
Author and year Benign mucinous cystic neoplasm (MCN) MCA with CIS or invasive cancer 
 N Average age 
in years 
(range) 
5 year 
survival 
Recurrence Average follow-up in 
months (range) 
N Average age in 
years 
(range) 
5 year survival Recurrence Average follow up in months 
(range) 
 
Fukushima 1997 7 6 53 (48-61) NR 0 80 (36-187) 4 44 (29-51) NR 
1 – DOD 
 
161 (20-257) 
Zamboni 1999 8 
40 
 
45 
(18-73) 
 
 
NR 
0 
 
 
 
LGD: 43 (4-114) 
IGD: 70 (9-180) 
22 
(6 with CIS) 
MCN + CIS: 
50 (27-78) 
Invasive MCA: 
56 (27-78) 
NR 
MCN + CIS: 0/6 
Invasive MCA: 8 /16– All DOD at 2, 
3, 4, 10, 12, 25, 27, 45 months 
(Median: 11 months). 
23 (2-134) 
Hara 2002 55 3 50 (36-65) NR 0 57 (34-77) 2 61 (52-69) NR 
MCN+CIS: 0/1 
Invasive MCA: 1 /1– DOD at 12 
months 
54 (12-96) 
Shimizu 2002 9 4 NR NR 0 57 (6-124) 
2 
(both with 
CIS) 
N/A NR MCN+CIS: 0/2 13 (15-80) 
Izumo, 2003 10 30 NR NR 0 62 (2-238) 4 NR NR 2 – both DOD 73 (4-245) 
Reddy, 2004 28 
50 
 
NR NR 0 (All MCNs: 15(1-203)) 
6 
(2 with CIS) 
Invasive MCA: 
51 (37-67) 
NR 
MCN+CIS: 0/2 
Invasive MCA: 3/4– all DOD 
(All MCNs: 15(1-203)) 
Sawai, 2004 56 6 NR NR 0 (All MCNs: 42 (4-95)) 
2 
 
NR NR 1 - DOD 
(All MCNs: 42 (4-95)) 
 
Suzuki, 2004 72 118 52 (19-8) 100% 0 NR 53 61 (61-85) 
MCN+CIS: 100% 
Invasive MCA: 
38% 
11 – all DOD NR 
Goh, 2005 71 17 NR NR 0 (All MCNs: 15 (0-63)) 
3 
(2 with CIS) 
NR NR 
MCN+CIS: 0/2 
Invasive MCA: 0/1 
(All MCNs: 15 (0-63)) 
Crippa, 2008 18 
135 
 
 
44 (16-79) 
 
 
Non-
invasive 
MCN: 100% 
0 (All MCNs: 57 (4-204)) 
28 
(9 with CIS) 
50 (27-82) 
Invasive MCA: 
57% 
MCN + CIS: 0/9 
Invasive MCA: 7/19 (37%) - all DOD 
6.5 months (range 2-17) after 
diagnosis. Mean recurrence occurred 
at 32.5 months (range, 4 – 99) 
(All MCNs: 57 (4-204)) 
Crippa, 2010 42 149 NR 
Non-
invasive 
MCN: 100% 
0 (All MCNs: 50 (2-233)) 
29 
(10 with CIS) 
NR 
Invasive MCA: 
58% 
MCN + CIS: 0/10 
Invasive MCA: 7/19 (37%) - all DOD 
6.5 months (range 2-17) after 
diagnosis. Mean recurrence occurred 
at 32.5 months (range, 4 – 99) 
(All MCNs: 50 (2-233)) 
Yamao, 2011 17 
129 
 
 
48 (NR) 99% 0 NR 
27 
(21 with CIS) 
 
51 (NR) 
 
MCN + CIS or 
invasive cancer: 
87% 
Invasive MCA: 
0% 
MCN+ CIS: 1/21 – DOD (possibly 
due to leakage of cyst contents) 
Invasive MCA: 2/6 – DOD 
NR 
Park, 2014 25 
86 
 
48 (NR) 
 
 
NR NR 40.5 (NR) 
9 
(5 with CIS) 
47 (NR) 
MCN+ CIS: 75% 
Invasive MCA: 
75% 
MCN+CIS: 0/5 
Invasive MCA: 1/4 
37.9 (NR) 
MCN: Mucinous Cystic Neoplasm, MCA: Mucinous Cystadenocarcinoma, DOD: Died of disease, CIS: Carcinoma in Situ, NR: Not recorded
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CHAPTER 2 
MULTICENTRE STUDY OF 211 RESECTED MCNS 
 
INTRODUCTION 
Pancreatic mucinous cystic neoplasms (MCN) have been defined by the World 
Health Organisation from 2000 as well-demarcated cystic lesions, lined by a mucin-
producing columnar epithelium overlying an ovarian-type stroma1-3. Although 
MCNs are relatively rare tumours, the overall incidence of Pancreatic Cystic 
Neoplasms (PCN) is increasing4-6. MCNs are estimated to account for between 10-
45% of all resected PCN7,8. 
Although MCNs are classified as neoplastic lesions9 their actual malignant potential 
remains uncertain, with rates of associated invasive cancer ranging anywhere 
between 0 and 34% in the current literature10. Associated malignancy was 
substantially higher in older studies, but these series included many larger lesions 
and lesions classified prior to the latest WHO pathological criteria for MCN, so 
may have inadvertently incorporated a proportion of intraductal papillary mucinous 
neoplasms (IPMNs), potentially explaining the higher rates of malignancy seen11. 
More recent series, although often describing a single centers experience, suggest 
that malignant transformation in MCN may be a much rarer finding, especially 
when the tumours are small in size (<4cm)12-16.  
The current management of a PCN is defined by a number of consensus guidelines 
from the International Association of Pancreatology (IAP)17, Europe18, and the 
American Gastroenterology Association19. The IAP and European guidelines 
specifically mention the management of MCN and both stipulate that where the 
diagnosis is certain and the patient is an operative candidate then surgical resection 
should be performed. Within the European consensus statement on cystic lesions of 
the pancreas, there is a proviso that where the diagnosis is uncertain and there are no 
associated worrisome features and the lesion is less than 4cm, then management of a 
MCN as a branch duct IPMN, with surveillance may be appropriate. However, to 
date very few studies have described the natural history of small MCNs to support 
this management strategy. 
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As the guidelines for MCN to date, have primarily advocated surgical resection, very 
few studies have described which worrisome features would predict malignant 
transformation if these lesions were to be surveyed. With the exception of a single 
multi-institution US study, worrisome features in MCN have been drawn from small 
singe centre experiences or extrapolated from findings in IPMN. Further large patient 
cohorts that have undergone careful classification and long-term follow up are 
therefore needed to better inform the natural history and optimal criteria for surgical 
resection in these lesions. 
The aims of this large multi-institution study are to determine the rate of associated 
malignancy in resected MCNs and to determine predictor features, clinical and 
radiological, for malignant transformation in MCN. 
 
PATIENTS AND METHODS  
Setting and study design: A multicentre retrospective study from nine pancreatic 
centres from across Europe. 
Inclusion criteria: In each centre all patients who had a MCN resected between 
January 1st 2003 and December 31st 2015 were included in the study. Cases were 
identified though individual unit’s pancreatic cyst databases, multidisciplinary team 
meeting records and pathology records.  
Exclusion Criteria: After a local review of the pathology report any patients with 
an MCN without ovarian-type stroma were excluded from the study. 
Data Recorded: For each patient, the medical records were reviewed in each centre 
and the following information, where available, was recorded in the study 
spreadsheet: name of hospital, gender, age at diagnosis and medical history (score 
of the American Society of Anaesthesiology (ASA score), diabetes, smoking, 
previous pancreatic disease, previous cancer, family history of cancer). Any 
associated symptoms were also recorded and an MCN was defined as symptomatic 
when identified on imaging performed for the evaluation of abdominal or back pain, 
obstructive jaundice, acute/recurrent pancreatitis or any documented history of 
recent weight loss. The following preoperative blood tests, when available, were 
recorded; amylase, serum carcinoembryonic antigen (CEA; normal range <4.0 
ng/mL), serum carbohydrate antigen 19-9 (CA 19-9; normal range <37 U/mL). 
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Radiological data recorded included type of scan; ultrasound, computed 
tomography (CT), magnetic resonance cholangiopancreatography (MRCP), 
endoscopic ultrasound (EUS), fine needle aspiration (FNA). From the cross-
sectional imaging (CT or MRI/MRCP), the following features were recorded 
including lesion size (maximal dimension), location and number of cystic lesions, 
presence of a solid component (mural nodules, solid component, calcification of 
the cyst or the wall, wall thickening), presence of septations, features of acute or 
chronic pancreatitis, and dilatation of the pancreatic duct to >6mm or biliary tree. 
For patients undergoing EUS-FNA, cytology and biochemistry (CEA and Amylase) 
results were also recorded. Operative details recorded included date of surgery and 
type of resection, post-operative adverse events (according to Clavien-Dindo 
grading), 30-day mortality, final histology, length of follow-up (time from surgery 
to the last MCN-related or other relevant outpatient appointment), follow-up 
imaging data and evidence of recurrence.  
Histopathological analysis. The diagnosis of an MCN was confirmed locally in 
each centre. Presence of ovarian type stroma was considered mandatory for the 
diagnosis and inclusion in the study. In cases where the original report was 
inconclusive and in all male patients a second review by an experienced local 
pancreatic pathologist was undertaken to confirm the diagnosis. Dysplasia was 
classified in accordance with the most aggressive histological epithelial changes as 
defined by the World Health Organisation (WHO) classification system9. Tumours 
were graded as having low or intermediate grade dysplasia, high-grade dysplasia 
including carcinoma in situ, and malignant when invasive carcinoma was present9.  
Statistics. All statistical analyses were performed using SPSS version 22.0 (SPSS 
Inc.,Chicago, IL, USA). In the tables, “n” indicates the number of patients with 
available data. Chi-square or Fisher's exact test was applied for analysis of 
categorical variables. Median values and inter-quartile ranges were considered for 
continuous variables. The non-parametric Manne-Whitney test was used to 
compare continuous variables. Multiple logistic regression models were used to 
identify independent factors for malignant transformation. Long-term survival was 
analysed using Kaplan Meier. Two-tailed p value of less than 0.05 was considered 
to be significant. 
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RESULTS  
Two hundred and eleven (211) patients with a histologically confirmed surgically 
resected MCN were included in the study. Median age at the time of surgery was 
53 (range 18–82) years and 95.7% (202/211) were women. 63% were considered 
symptomatic and in 37% the MCN was an incidental finding. 89.6% patients had a 
CT scan, with the remainder having an MRI/MRCP. 28.4% patients had both a CT 
and MRI. Pre-operatively, the median tumor size was 55 (range 12-230) mm and 
an MCN was suspected in 49.7%, an IPMN in 11.6% and the lesion remained 
indeterminate in 38.8%. Mural nodules were present in 23.4%, cyst wall 
calcification in 18.8% and septations in 52.9% of the cases. In 8.8% the diameter 
of the main pancreatic duct was ≥6 mm [Table1]. 39% patients had an EUS and a 
fine needle aspiration was performed in 28%. Cytology had a sensitivity, 
specificity, PPV and NPV of 66.67%, 98.11%, 66.67%, 98.11% respectively for 
malignant transformation. 
A distal pancreatectomy was performed in 82.9%, pancreatico-duodenectomy in 
8.5% and an enucleation in 4.3%. 30-day morbidity was 0.9% with a 30-day 
morbidity of 37.9%; Clavien-Dindo Grade 1 in10.4%, Grade 2 in15.2%, Grade 3 
in 9.5%, Grade 4 in 1.9% and Grade 5 in 0.9% of patients. 
The median resected tumor size was 55.5 (range 20-300) mm. Invasive cancer was 
present in 16.1% (34/211), with high-grade dysplasia (HGD) seen in a further 6.2% 
(13/211) of patients. For patients with invasive MCN cancer, the tumour was 
classified as stage Ia in 9 (26.5%) patients, stage Ib in 8 (23.5%), stage IIa in 6 
(17.6%), stage IIb in 6 (17.6%) and stage III in 5 (14.7%) patients. An R0 resection 
was achieved in 58.8% (20/34) of the cases. 
Malignant transformation was associated with presence of symptoms (88.2 vs 
58.2%; p=0.001), especially those presenting with pancreatitis (26.5 vs 9.6%; 
p=0.018), jaundice (20.6 vs. 1.7%; p<0.0001), or who had significant weight loss 
(32.3 vs. 6.2%; p<0.0001), and had elevated serum CA19-9 (68.8 vs 16.0%; 
p<0.001) [Table 2]. 
The rate of invasive cancer correlated with increasing tumour size [Figure 1a]. In 
lesions greater than 12 cm the rate invasive cancer was 45.8% compared to just 
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10% in lesions less than 4 cm and 5% in lesions less than 3 cm. Five cases of 
invasive cancer occurred in patients less than 4cm in size and like all cases of 
invasive malignancy in this study, they were all associated with at least one pre-
operative feature of concern [Table 4]. When stratified by sex the rate of 
malignancy in lesions less than 4cm in female patients decreased to 2.9% (HGD 
5.9%) compared to 25% in men (HGD 25%) [Figure 1b and c].  
On univariate analysis, we found that, presence of symptoms, previous pancreatitis, 
jaundice, raised Ca19-9, recent weight loss, tumour size, and mural nodules were 
associated with invasive cancer. On multivariable analysis, weight loss (OR 2.703; 
95% CI 1.501–14.569, p=0.004), raised CA19-9 (OR 10.874; 95% CI 1.888–
24.533, p<0.001), tumour size (OR 1.019; 95% CI 1.003–1.035, p=0.020) and 
mural nodules (OR 6.856; 95% CI 1.302–36.111, p=0.023) were found to be 
independent factors of malignant transformation. The model was a good predictor 
of malignant transformation with Nagelklerke R Square value of 0.711 [Table 3]. 
Median survival for patients with a malignant MCN was 44 months (range 0-167 
months), 12 patients died during the follow up; 10 from disease recurrence. 
Although not significant, the survival trend was also worse in male patients than 
female patients (Figure 2).  
 
DISCUSSION 
MCNs are neoplastic cystic tumours of the pancreas, which have the potential to 
evolve into an invasive cancer. They have been classified separately from IPMNs 
by the World Health Organization (WHO) since 19962, and the Armed Forces 
Institute of Pathology (AFIP) from 19973.  In this large cohort of patients, resected 
after the introduction of the new pathological classification of MCN, the overall 
rate of associated invasive cancer was low; 16.1% compared to up to 34% in some 
earlier publications10. Rates of HGD were lower than in other singles centre 
series12,16,20  at 6.2% but similar to the rate found in a recent multicentre study from 
North America21.  
In real life, differentiating small MCN from other uni- and oligocystic tumors (i.e. 
branch duct-IPMN and serous cystadenoma) remains a significant clinical 
challenge, as to date features which predict invasive malignancy in MCN have been 
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poorly characterised and often overlap with other cystic lesions of the pancreas14. 
The pre-operative uncertainty in defining these lesions was clearly reflected in this 
study with less then 50% of MCNs being correctly classified prior to resection. 
Current guidelines are clear and consistent when the diagnosis of MCN is certain, 
recommending surgical resection. However when the pre-operative diagnosis is less 
clear, as in a large proportion of cases in this study the European guidelines, have 
suggested that if the lesion is small in size (<4cm) and is without worrisome feature, 
then a period of surveillance may be appropriate to better define the diagnosis prior 
to surgery, however few studies have explored the natural history of MCN to 
support the safely of this proposed management strategy18. Over time the size at 
which MCNs are detected has decreased. In these small lesions features of concern 
are often absent, so cyst diameter has remained the most important radiologic 
predictor of malignant transformation. At what size patients should be referred for 
surgical resection in MCN remains uncertain. As part of this large cohort study we 
therefore compared the rate of invasive malignancy and HGD of different size 
lesions. Invasive cancer occurred in 9.8% in lesions less than 4cm and 5.3% less 
than 3cm. In the five cases of invasive cancer in lesions less than 4cm, like with all 
cases of cancer or HGD in this study, at least one pre-operative worrisome feature 
was present to prompt surgical management. When stratified by sex the rate of 
associated invasive cancer in women with lesions less than 4cm was 5.5% and in 
lesions less than 3cm was just 2.9%.  Although this is retrospective data drawn from 
surgically resected cases and will need to be confirmed by prospective surveillance 
studies, these finding do support the conservative management of MCN advocated 
by the European guidelines, particularly in women with suspected MCNs without 
worrisome features that are small in size (<4cm). Low rates of malignant 
transformation in small MCN without worrisome features has been observed in 
other case series12,16,20,22-25. Which features other than size, that predicts malignant 
transformation in MCN, has often been poorly defined and extrapolated from mixed 
PCN cohorts. Therefore, in the second part of this study we aimed to better define 
worrisome feature for this lesion. On multivariate analysis, apart from lesion size, 
we found that raised Ca 19-9 and solid component were predictive of invasive 
cancer. MCN differ from other PCN, predominantly occurring in female patients. 
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Whether MCNs, defined by the presence of ovarian-type stroma, can even occur in 
male patients has been debated26, but a number of case reports in male patients have 
been reported12,16,20. In this study with careful pathological characterization, just 
4.3% occurred in men, one of the lowest rates reported to date. Rates of invasive 
caner and high-grade dysplasia were also more common in men than women and 
appeared to occur at an earlier stage when the lesions were still small in size, [Table 
2]. Surgical resection should therefore always be considered in male patients with 
a suspected MCN.  In addition to tumour size this study also found that a raised CA 
19-9 and solid component were also independent predictors of invasive cancer. Other 
case series and multicentre studies have also suggested CA19-9 as risk factor for 
malignancy in MCN.(16, 21) A solid component or the presence of a mural nodule 
has also been consistently identified by a number of studies and suggested as the most 
reliable factor to predict malignancy in MCN12,14,16,22,25,28,29. This data in addition to 
defining which cases of MCN can be safely surveyed when the pre-operative 
diagnosis is unclear, also allows us to define a cohort of patients who may be 
suitable for non-radical resection or emerging ablative techniques. It also allows us 
to better quantify actual risk of malignancy in patients who are unfit for surgery or 
who refuse surgery for any reason.  The median survival of patients with a 
malignant MCN in this study was 44 months (range 0-167 months) which is similar 
to other types of malignant PCN and superior to pancreatic ductal adenocarcinoma8. 
However, a trend towards worse survival was also observed in male patients, which 
was somewhat unexpected and perhaps further supports the apparent aggressive 
nature of MCN in male patients. In other female predominant PCN such as solid 
pseudopapillary tumours, male patients have also been observed to have a poorer 
prognosis27.  
Strengths and Limitations. This study has several strengths, it analyses a large 
cohort of carefully characterized patients with a pathologically confirmed MCN, 
where ovarian-type stoma was present in all cases. The dataset includes 
comprehensive demographic, clinical, radiological, surgical, pathological and 
follow-up data, which has allowed us to better define features, which predict 
malignant transformation. Potential limitations include that most cases have been 
recruited from tertiary referral centres, so the proportion of high-risk lesions and 
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malignant cases may be higher. Large community based cohorts and surveillance 
cohorts of PCN have reported much lower incidences of associated malignancy29. 
However, without being able to pathologically define MCN lesions it would be 
impossible to carry out this study in this group. Some patients included in the study, 
may have been included in previously reported case series. 
 
CONCLUSION 
In conclusion, in female patients in this large multicentre study, malignancy or 
HGD was solely seen in MCNs with symptoms or worrisome features on 
preoperative imaging, regardless of the size of the tumour. In males, the risk of 
malignancy was significantly higher than in females, suggesting that operative 
treatment should be considered in all male patients with a suspected MCN of any 
size. In female patients conservative management seems to be a safe approach for 
suspected MCNs of any size without symptoms or worrisome features.  
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TABLES AND FIGURES 
 
Table 1. Characteristics and radiological features of study cohort. 
 % N 
Demographics and clinical symptoms    
Sex 
• Male 
• Female 
 
4.3 
95.7 
 
9/211 
202/211  
Age, years median (interquartile range)  53 (43-63) 
BMI, median (interquartile range)  25 (23-29) 
Presence of symptoms 
• Abdominal pain 
• Acute or recurrent pancreatitis 
• Weight loss 
• Jaundice 
63.0 
46.0 
12.3 
10.4 
4.7 
133/211  
97/211 
26/211 
22/211 
10/211 
Pre-operative radiological features   
Location 
• Head/uncinate 
• Body 
• Tail 
• Missing data 
 
10.9 
27.5 
55.9 
5.7 
 
23/211 
58/211 
118/211  
12/211 
Tumour size, mm median (interquartile range)  55 (30-91) 
Mural nodules 23.4 37/158 
Cyst wall calcifications 18.8 32/170 
Dilated main pancreatic duct  8.8 14/159 
Septations 52.9 83/157 
Suspected pre-operative diagnosis 
• MCN 
• IPMN 
• Uncertain 
 
49.7 
11.6 
38.8 
 
73/147 
17/147 
57/147 
Surgery performed and outcomes   
Type of surgery 
• Distal pancreatectomy 
• Pancreatico-duodenectomy 
• Enucleation 
• Other* 
 
82.9 
8.5 
4.3 
4.3 
 
175/211 
18/211 
9/211 
9/211 
30-day adverse events 37.9 80/211 
Peri-operative 30-day mortality 0.9 2/211 
Presence of invasive cancer 16.1 34/211 
* Includes total pancreatectomies and multi-visceral resections. BMI Body Mass Index. 
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Table 2. Features of benign and malignant MCN stratified by sex. 
 
 All patients (n=211) Female (n=202) Male (n=9) 
 Patients with 
invasive cancer 
(n = 34) 
Patients with 
benign disease 
including HGD 
(n=177) 
p value 
Patients with 
invasive cancer 
(n = 31) 
 
Patients with 
benign disease 
including HGD 
(n=171) 
p value 
Patients with 
invasive cancer 
(n=3) 
Patients with 
benign disease 
including HGD 
(n=6) 
 
p value 
Risk factors, clinical symptoms and serum tumour markers 
Male 3 (8.8) 6 (3.4) 0.161       
Age, years median 
(interquartile range) 
55 (44-66) 52 (43-62) 0.349 53 (43-64) 51 (43-61) 0.565 68 (64-68) 70 (60-79) 0.905 
Smoking  5 (35.7) 29 (29.3) 0.765 3 (25.0) 27 (28.7) 1.000 2 (100) 2 (40) 0.429 
BMI, median (interquartile 
range) 
25 (23-28) 26 (23-29) 0.732 25 (23-29) 25 (23-30) 0.943 24 (22-24) 27 (24-28) 0.250 
Diabetes mellitus 1 (3.3) 14 (8.5) 0.475 1 (3.7) 12 (7.5) 0.696 0 (0.0) 2 (33.3) 0.50 
Presence of symptoms  30 (88.2) 103 (58.2) 0.001 27 (87.1) 98 (57.3) 0.001 3 (100.0) 5 (83.3) 1.000 
Jaundice  7 (20.6) 3 (1.7) <0.001 5 (16.1) 2 (1.2) 0.001 2 (66.7) 1 (16.7) 0.226 
History of pancreatitis  9 (26.5) 17 (9.6) 0.018 8 (25.8) 15 (8.8) 0.012 1 (33.3) 2 (33.3) 1.000 
Recent weight loss  11 (32.4) 11 (6.2) <0.001 8 (25.8) 10 (5.8) 0.002 3 (100.0) 1 (16.7) 0.048 
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Raised serum Ca19-9 11 (68.8) 13 (16.0) <0.0001 9 (69.2) 13 (16.9) <0.001 2 (66.7) 0 (0.0) 0.143 
Cross-sectional imaging features 
Size of tumour, mm median 
(interquartile range) 
100 (45-131) 52 (30-85) 0.001 111 (54-133) 52 (30-86) <0.001 30 (28-30) 33 (17-49) 0.714 
Mural nodules  12 (60.0) 25 (18.1) <0.001 10 (58.8) 22 (16.5) <0.001 2 (66.7) 3 (60.0) 0.741 
Dilation of the main pancreatic 
duct 
4 (21.1) 10 (7.1) 0.067 3 (18.8) 7 (5.2) 0.074 1 (33.3) 3 (60.0) 1.00 
Septations  12 (57.1) 71 (52.2) 0.815 10 (55.6) 70 (53.4) 1.000 2 (66.7) 1 (20.0) 0.464 
Cyst wall calcification  7 (35.0) 25 (19.4 0.142 6 (35.3) 24 (19.4) 0.201 1 (33.3) 1 (20.0) 1.000 
Head location 7 (20.6) 16 (9.0) 0.067 4 (12.9) 13 (7.6) 0.304 3 (100) 3 (50) 0.464 
CBD dilatation 4 (18.2) 4 (3.0) 0.014 2 (10.5) 3 (2.3) 0.122 2 (66.7) 1 (20.0) 0.464 
Data are presented as absolute number (percentage) unless otherwise indicated. BMI Body Mass Index CBD Commune Bile Duct.  
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Table 3. Binary Logistic Regression of Preoperative Risk Factors for invasive 
adenocarcinoma in mucinous cystic neoplasms 
 
Variable Univariate analysis  Multivariate analysis 
Clinical features OR (95% CI) 
p 
value 
 OR (95% CI) 
p 
value 
Male gender 
2.758 (0.655-
11.615) 
0.167 
 
 NS 
Symptomatic  
5.388 (1.820-
15.949) 
0.002 
 
 NS 
History of 
pancreatitis 
3.388 (1.362-
8.428) 
0.009 
 
 NS 
Jaundice 
15.037 (3.664-
61.712) 
<0.001 
 
 NS 
Weight loss 
7.217 (2.812-
18.526) 
<0.001 
 
2.703 (1.501-14.569) 0.004 
Serum Ca19-9 
11.508 (3.424-
38.677) 
<0.001 
 
10.874 (1.888-24.533) <0.001 
Median size (mm) 
1.017 (1.008-
1.026) 
<0.001 
 
1.019 (1.003-1.035) 0.02 
Tumour location: 
Head of pancreas 
2.609 (0.982-
6.932) 
0.054 
 
 NS 
Solid component 
6.780 (2.509-
18.319) 
<0.001 
 
6.856 (1.302-36.111) 0.023 
Dilation of main 
pancreatic duct 
3.467 (0.967-
12.428) 
0.056 
 
 NS 
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Table 4.  Age, sex, worrisome features associated with invasive MCNs of less than 
4cm  
  
Age Sex 
Tumour 
size 
Worrisome features 
Case 1 74 F 33 
Symptoms, raised Ca 19-9, dilated main 
PD 
Case 2 70 M 28 
Symptoms, raised Ca 19-9, mural 
nodules, cyst wall calcification, 
septations 
Case 3 37 F 35 Symptoms, mural nodules 
Case 4 64 M 30 
Symptoms, raised Ca 19-9, septations, 
dilated CBD 
Case 5 65 F 16 Symptoms 
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Figure 1a. Prevalence of invasive cancer at different tumour sizes  
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Figure 1b. Prevalence of invasive cancer at different tumour sizes in women 
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Figure 1c. Prevalence of invasive cancer at different tumour sizes in men 
<3 cm <4 cm
4.0-7.9
cm
8.0-11.9
cm
>12 cm
No atypia or LGD or IGD
(%)
50 40 75 0 0
HGD (%) 25 20 0 0 0
Invasive cancer (%) 25 40 25 0 0
0
20
40
60
80
100
120
%
42 
 
Figure 2.  Kaplan-Meier curve for patients undergoing surgical resection for 
invasive MCNs in men and women (n=34). 
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CHAPTER 3 
MCNS AND PREGNANCY 
 
INTRODUCTION 
Mucinous Cystic Neoplasms (MCN) of the pancreas are neoplastic cysts lined by 
mucin-producing columnar epithelium and a distinctive ovarian-type stroma (OS) 
underlying it, as a characteristic histological feature 1,2. Nowadays, they are being 
diagnosed with increasing frequency due to the aging population and the 
widespread of cross-sectional imaging3,4, but few studies have been performed 
investigating their true incidence or prevalence. Some papers show that they 
account between 10-45% of all resected pancreatic cystic neoplasms (PCN), and 
together with IPMN (Intraductal Papillary Mucinous Neoplasms), they represent 
the majority of neoplastic cysts of the pancreas.5-7 MCN occur almost exclusively 
in women (98-99.7%; female: male ratio 20:1), usually in peri-menopausal period 
(women aged 40-60 years), with the incidence peak in the 5th decade.8,9 They are 
almost always located in the pancreatic body or tail (93%), without communication 
to pancreatic ducts. They use to be asymptomatic lesions, often found incidentally. 
The female predominance, presence of ovarian stroma, and estrogen (ER) and/or 
progesterone hormone receptors (PR), are findings that strongly suggest an 
hormonal dependence, but this relationship still remains unclear.10,11 In fact, similar 
mucinous cystic tumors have been found in other organs, like the Hepatobiliary 
Cystadenoma or Cystadenocarcinoma and Mixed Epithelial and Stromal Tumor of 
the kidney (MEST) described almost exclusively in women and with a 
characteristic OS10,12. It is widely known that pancreatic MCNs always carry 
malignant potential, but real data are unknown, with reported rates of malignancy 
between 4-34%.13 Nevertheless, latest single centre case-series14-17 and clinical 
practice suggest that the majority of them are benign cysts with slow growth (less 
than 1cm per year), and with an excellent prognosis, even when High Grade 
Dysplasia (HGD) is present, in the absence of invasive disease.6,18,19 This 
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uncertainty surrounding their natural history makes surgical criteria differ among 
different consensus guidelines.20-22 
A special and extremely rare circumstance is the diagnosis of MCN during 
pregnancy, and nowadays it represents a huge clinical challenge. A growing number 
of papers reporting such cases are appearing during last years, and they seem to 
show a certainly different behaviour when these tumors develop in pregnant 
women, with a possible role for female sex hormones in a faster tumorigenesis and 
malignant transformation that remains unclear. Besides, pre-surgical diagnostic 
process is limited to non-ionizing imaging techniques such as abdominal ultrasound 
or MRI and invasive techniques like EUS are not always recommended (EUS), so 
the evidence of invasive malignancy can be frequently inconclusive in the moment 
of diagnose. The risk of severe associated complications, Foetal Intrauterine 
Growth Restriction or rupture of the cyst related to Valsalva during vaginal delivery 
are other uncertainties that remains unknown. In this context, best time for surgery 
is also unclear, being the most important goal minimal maternal and foetal risk.  
In conclusion, to date there is no evidence enough to suggest the correct rules for 
the management of MNCs associated with pregnancy. The aim of this chapter is to 
establish a management protocol by analysing 3 cases from our clinical experience 
and all cases reported in the literature, drawing on demographic, diagnostic, 
therapeutic and prognostic data.  
 
Case 1. Zaragoza, Spain. February 2008 
A 37-year-old woman gravida1-para1 was referred to our department after being 
operated by laparoscopy in relation to ectopic pregnancy (10th week of pregnancy). 
During surgery, a cystic tumor of 8cm was discovered in the pancreatic tail. 
Abdominal Ultrasound performed 2 months before didn´t show any abnormal 
finding. Abdominal Ultrasound and Abdominal C after surgery, showed a large (80 
x 60 cm), well circumscribed hypoechoic cystic tumor at the upper left abdominal 
quadrant, with no mural nodules inside de cyst. The final diagnose of pancreatic 
mucinous cystadenoma was established. Despite its size, patient didn´t mention any 
complaint or clinical sign and abdominal palpation was normal. Serum analysis 
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including levels of tumor markers (CEA, Ca 19-9), Amylase, and all other blood 
laboratory determinations were within normal limits.45 days after laparotomy, 
resection of the tumor with distal pancreatectomy was performed. Because no sign 
of invasion was observed, the spleen was preserved. Histology showed a columnar 
mucinous epithelium lining the inner walls of the cystic tumor, without atypia or 
abnormal mitotic activity and with an OS under it. The diagnosis was benign MCN, 
with tumor-free margins and nonaffected lymph nodes (R0 Resection). 
Immunohistochemistry for ER) and/or PR was not developed. The annually follow 
up didn`t show any recurrence and the patient has been asymptomatic during the 
follow up period. 
 
Case 2. Tampere, Finland 
A 28 years old women, had abdominal pain secondary to acute pancreatitis during 
the first trimester of her pregnancy. An Us scan showed a big pancreatic mass to 
the tail of the pancreas. MRI scan confirmed the presence of 8 cm mass associated 
with mural nodules. The diagnosis of symptomatic MCN associated with 
radiological features of malignancy was made. Following MDT, the plan for distal 
pancreatectomy during the second trimester was concorded.  The patient had a distal 
pancreatectomy as planned. he had normal post-operative course without any 
complication. The histology showed MCN with high grade dysplasia. She had a 
vaginal delivery at 42 weeks without any complications. The annually follow up 
didn`t show any recurrence and the patient has been asymptomatic during the 
follow up period. 
 
Case 3. Southampton, Great Britain 
 A 23-year-old woman had back and epigastric pain during her pregnancy. 
Abdominal Us scan showed pancreatic cyst in the tail (no size was mentioned). 
Never had pain before. The patient didn`t attend her clinical appointments for 
further investigations. 1 years later, the patient came back to the clinic for 
abdominal pain. She was extensively investigated by; abdominal Us scan, Ct scan, 
MRCP and EUS which showed 6x7 cm cystic mass at the pancreatic tail. The 
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diagnosis of Mucinous cystadenoma was established. In presence of symptoms and 
the size of the lesion, the decision for distal Pancreatectomy was made. She had 
normal post-operative course without any complication. The histology showed a 
columnar mucinous epithelium lining the internal wall of the cyst, with an ovarian 
type Struma, absence of cancer. The diagnosis of benign MCN was made. 
Immunohistochemistry for estrogen and/or progesterone receptors was not done. 
The annually follow up didn`t show any recurrence and the patient has been 
asymptomatic during the follow up period. 
 
MATERIAL AND METHODS  
In addition to our 3 cases identified in our multicentre database, covering operated 
MCNs between 2003-2015, a literature search (PubMed database, Embase, 
Cochrane Library) for articles published between January 1970-January 2016 was 
performed, using the following search terms, decided by a consensus of the authors: 
pancreas AND mucinous cystic neoplasm OR mucinous cyst AND pregnancy OR 
delivery. Only English and Japanese-language reports were identified, and we 
didn´t apply any language limitation. The search was restricted to title, abstract and 
keywords. Only lesions detected during pregnancy or during postpartum in a clear 
temporary relationship with pregnancy period were included.  
A total of 30 cases were selected. In 22 of them there was no diagnostic doubt 
because the presence of ovarian-type Struma (OS) was specified in pathologic 
description (Table 1). 
Those cases in which the presence of OS was not mentioned (a total of 8), were 
selected using the following criteria: We only consider those lesions with 
morphological characteristics described that made confusion with other pancreatic 
cysts virtually impossible. Must meet two or more of the following requirements: 
final pathologic diagnose of MCN (even without mentioning OS), typical location 
in body/tail, big size, lack of communication with the pancreatic duct (Table 2).  
The following variables were extracted when available: age and gestational age at 
diagnose, number of previous pregnancies, medical history (at least 6 months 
before), gestational diabetes, symptoms, complications and physical examination, 
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size, location and evidenced growth, serum levels of CEA, Ca19.9, Amylase and 
Hemoglobin, diagnose imaging techniques and presence of high risk features, 
pathological diagnose, presence of ovarian stroma, grade of dysplasia/invasive 
carcinoma, hormonal receptors, analysis of cystic fluid, surgery time, surgical 
complications, length of follow-up, type of delivery, maternal and fetal prognosis.  
 
RESULTS  
30 operated MCN cases diagnosed during pregnancy were included in the study. 
All lesions had a pathological diagnosis of MCN, and in 22/30 (73.3%) ovarian type 
stroma was reported.   
Epidemiology  
The median age at diagnose was 30.5 years (range 21-38). 8/25 cases (32%) were 
diagnosed during first pregnancy, 15/25 cases (60%) during second pregnancy, and 
only 2 women had had 3 or more pregnancies before. 12/30 cases, (40%) were 
diagnosed during the first trimester, 8/30 (26.7%) during the second trimester, 4/30 
during the third trimester and 6/30 after delivery (range 1-8 months after delivery).  
Morphological Characteristics  
27/30 lesions (93.4%) were located in the body and/or tail of the pancreas (2 in the 
body (6.7%), 14 in the tail (46.7%), and 12 (40%) in both body and tail). Only in 2 
cases (6.7%) it was reported in the head.  Median tumor size at diagnose was 11.73 
cm (range 4.5-19 cm). The rate of cyst growth during pregnancy was monitored in 
12 patients, and was faster than reported in MCNs in general (< 1cm per year). 
Calculated median growth was 3.67 (range 1-6.8 cm) from within the median 3.5 
months (range 1-8 months) approximately, from diagnosis to operation.   
Clinical presentation 
At least 6 months prior to diagnosis, 13/30 (43.3%) patients were asymptomatic. At 
the time of diagnosis, 21/30 cases (70%) were associated with abdominal 
discomfort/pain, 16/30 (53.3%) showed a palpable abdominal mass, and only 6/30 
(20%) were incidental findings. Complications secondary to the MCNs were found 
in 7/30 patients (23.3%): 2/7 had acute Pancreatitis, 2/7 had upper Gastrointestinal 
Bleeding and 3/7 cases were complicated by acute Abdomen secondary to tumor 
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rupture requiring urgent operation during the first or third trimesters.  
Diagnosis and pre-operative investigations 
In 23/28 cases (82.1%), first diagnostic imaging technique was Abdominal 
Ultrasound, and a Magnetic Resonance completed the study in 14/28 (50%) of these 
cases. Only 5 women (17,9%) were studied by EUS, with only 2 FNA that were not 
informative. In 2 cases the diagnosis of the cyst was made intraoperatively by 
emergency surgery (caesarean delivery due to acute abdominal pain in an advanced 
pregnancy of 36 weeks, urgent laparotomy due to acute abdomen and suspected 
ectopic pregnancy). High Risk features were identified in 6/27 cases (22,2%), all of 
them with MR and/or EUS. All cases were described like “mural nodules” or “mass 
forming lesions inside the cyst” with no cases of egg peripheral calcifications 
described. Only 3/6 (50%) of these pre-surgery high risk lesions were confirmed as 
high grade dysplasia (2) or invasive carcinoma (1) in the later pathological 
analysis. On the other side, 2 cases of HGD and 4 cases of Invasive Carcinoma 
didn´t show any High-Risk features during the imaging pre-operative 
investigations, however, 3 of them were studied only by Abdominal Ultrasound.  
Cystic fluid analysis: Cyst fluid analysis had a mucinous appearance in 17/21 cases 
(80.9%). In most cases (16/21) it was obtained during surgery. Cyst fluid CEA was 
elevated in all the 8 cases where it was measured (range 837-66.898 ng/ml). 50% 
of these cases showed HRD/IC (range 837-66898ng/ml), but the other 50% didn´t 
show any malignancy in the pathological analysis (range 2219-32800ng/ml), 
confirming its low predictive value for malignancy. Cyst fluid Ca 19.9 was 
measured in 6 cases (range 22->50000 UI/ml), only in 2 cases levels were <1000 
UI/ml. 2/4 cases with Ca 19.9 level > 1000UI/ml showed HGD / IC, and curiously 
the case with the lowest level (22 IU /ml) showed HGD too. Cyst fluid Amylase 
was reported in 5 cases, always < 500 UI/l (range 7-463UI/l), endorsing the lack of 
communication with the main pancreatic duct.  
Surgery  
Most the cases were operated on in the second trimester (11/30 (37.5%)) or 
postpartum (14/30 (44.8%)). 5/30 cases (17.7%) needed to be urgently operated on 
in the first (3/30) or third trimesters (2/30) due to severe complications associated. 
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According to the location of lesions, in 25/30 cases a Distal Pancreatectomy was 
performed, in 1/30 a Pancreatico-duodenectomy and 4/30 Enucleations.  
Pathology 
High Grade Dysplasia or Invasive Cancer was present in 5/30 (16,7%) and 7/30 
(23,3%) respectively. The immune- histochemical analysis was reported in 19 
cases, with a positive result for hormonal receptors (progesterone (PgR) and/or 
estrogen (EsR)) in 14/19 (73,7%) of cases, with the following distribution: 10/19 
PgR&EsR (+), 3 PgR(+), 1EsR(+) and 5 PgR&EsR (-).  
Delivery and follow up  
Natural (vaginal) delivery was possible in 20/30 cases (66,7%), 7 of them operated 
during the postpartum with cyst sizes ranging 4,5-16cm, demonstrating a low risk 
of rupture of the cyst with the Valsalva maneuver.  Cesarean was necessary in 
23.3% of cases (7/30), 1 case of ectopic pregnancy and 2 abortions were reported: 
1 spontaneous abortion in 10th week of gestation not thought to be associated with 
the MCN, and 1 voluntary interruption of pregnancy at 8th week.  
Despite the high rate of malignant transformation, during the follow-up no cases of 
systemic recurrence were observed and local recurrence occurred only in 3/27 
cases: one following an R1 resection, one with a synchronous anaplastic pancreatic 
carcinoma, and one ruptured MCN with an associated invasive carcinoma. With a 
median follow up of 32 (range 6-132) months, fetal and maternal prognosis after 
delivery was excellent. 
 
DISCUSSION  
Pancreatic MCN are lesions with female predominance, characterized by the 
existence of an underlying ovarian stroma with estrogen and progesterone 
receptors, not found in other pancreatic neoplasms. These data strongly suggest that 
their appearance and subsequent development may have a clear hormonal 
dependence. In fact, similar mucinous cystic tumors have been found in other 
organs, like the Hepatobiliary Cystadenoma or Cystadenocarcinoma and Mixed 
Epithelial and Stromal Tumor of the kidney (MEST) described almost exclusively 
in women and with a characteristic ovarian stroma.10,12  
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Under normal conditions, they occur during perimenopause period, being usually 
small, asymptomatic, and with a slow growth rate (<1 cm per year). Its appearance 
during pregnancy is an extremely rare condition but its behavior is clearly different, 
probably in relation to their responsiveness to high levels female sex hormones, as 
the results described in our series shown.  
Pancreatic MCN diagnosed during pregnancy appear at a much younger age and 
they are more frequent in women with 1 or more previous pregnancies, with no 
differences regarding the trimester in which the diagnosis occurs.  
Regarding to the location within the gland, the MCN in pregnancy have the same 
distribution of the rest of MCN, being more frequent in pancreatic body and/or tail 
(93,7%). 
Mean size at diagnosis tends to be larger than usual (11.3cm vs 8,7cm9,23 and often 
develop more rapidly. In our series, they show a mean growth rate 3.67cm in a 
median of 3.5 months approximately, from diagnosis to operation, getting even, in 
some cases, to double its size in a few months.11 
In our opinion, a possible explanation to its larger size and growth rate is the strong 
hormonal activity during pregnancy and its influence on the ovarian stroma. The 
origin of ovarian stroma in MCN of the pancreas is unknown. Zamboni et al18 have 
proposed that the primitive mesenchyme and endoderm-derived epithelium in 
organs such as the pancreas and liver could proliferate because of hypersensitivity 
to female sex hormone stimulation exacerbated during pregnancy. An alternative 
hypothesis is that primary yolk cells were implanted into the pancreas erroneously 
due to the proximity of the genital tract to the dorsal pancreas during 7th week of 
embryogenesis. The dorsal pancreatic enlarge gives rise mainly to the pancreatic 
body and tail, and this could explain the predilection of MCN for the distal pancreas. 
Whatever the origin was, this tissue has hormonal receptors to progesterone and or 
estrogen. In our series, 73,7% cases showed positivity to hormonal receptors in the 
immune-histochemical analysis.  
Another observation suggesting the possible hormonal influence in MCN 
development is the case reported by Tanaka et al24 in a 53-years-old woman with a 
10-year history of a stable pancreatic cyst, that after starting hormone replacement 
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therapy experimented a gradual increase of the size of the cyst, which after 
pancreatectomy was diagnosed as an MCN carcinoma.  
  
If high levels of estrogen and/or progesterone during pregnancy can increase the 
cyst malignancy potential and favor malignant transformation remains still unclear. 
In fact, there is some evidence about the correlation between a worse prognosis in 
cyst with histological atypicality and a decrease in progesterone receptor 
immunoreactivity. But as the size is considered a risk factor for malignancy on its 
own, and the rapid proliferation may be an additional risk factor, MCN diagnosed 
during pregnancy should be considered high-risk lesions. Our results support this 
theory, and malignancy (HGD or Invasive Cancer) was present in 40% cases, 
clearly superior to that described for the MCN outside the time of pregnancy (12-
20%).14,23 
At diagnosis, most lesions are symptomatic, and severe associated complications 
are frequent (24,7%). These facts can have a double explanation. First, the larger 
size of the cysts and especially the higher growth rate can promote early onset of 
symptoms. Second, the high rate of malignancy can also be the cause of symptoms. 
Thus, the guidelines and expert consensus for management of MCN consider the 
appearance of symptoms as a risk criteria for malignancy, recommending surgical 
removal.  
In our series, most cases didn´t show any warning symptoms during at least 6 
months before diagnosis, which supports that the cyst did not exist before 
pregnancy, or at least that it began its growth at the same time. Another fact 
supporting this theory is that most patients with a growing palpable mass, a small 
pancreatic cyst had been diagnosed in a previous pregnancy.  
Most common symptom observed in our series was epigastric abdominal pain or 
discomfort or the presence of a palpable abdominal mass. Jaundice was not a 
frequent symptom in these patients, probably related to its unusual location in 
pancreatic head.  
Diagnostic process of MCN during pregnancy is limited to non-ionizing imaging 
techniques. In our series, Abdominal Ultrasound, Magnetic Resonance and 
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Endoscopic Ultrasound were useful techniques for diagnosis but they were 
worthless to detect high risk features for malignancy (MR positive predictive value 
50%). However, our series has the limitation of being a historical series with many 
cases reported before 2000, in which availability and quality of MR and EUS would 
be probably much lower than today. According to the known reported data, the 
diagnostic value of cytology observed in our series was very low, so that the 
probably advisable diagnostic test for MCN associated with pregnancy remains the 
MRI, despite its insufficient accuracy, especially considering the invasiveness and 
low superiority of EUS-FNA.   
Most patients were operated during the second trimester of pregnancy (traditionally 
considered the safest) or during postpartum. In our series, only a single case of 
MCN related complications was reported in a woman who was operated in the 
second trimester. A very important step is to decide the most appropriate modality 
of delivery. Theoretically, a large pancreatic cystic mass can induce Intrauterine 
Growth Restrictions with specific fetal morbidity11,19 and cystic rupture  
In our series, uneventful vaginal delivery was possible in 67% of cases. No cases 
of cyst rupture related to Valsalva or Intrauterine Growth Restriction was reported.   
With a median follow up of 32 (range 6-132) months, fetal and maternal prognosis 
after delivery was excellent, with only 3 cases reported of local recurrence in 
relation with poor prognosis factors: one case following an R1 resection, one with 
a synchronous anaplastic pancreatic carcinoma, and one ruptured MCN with an 
associated invasive carcinoma.  
  
CONCLUSION  
Pancreatic MCNs diagnosed during pregnancy are often large and grow rapidly. 
They appear predominantly in younger women, with one or more previous 
pregnancies. Most lesions are symptomatic at diagnose. The Immuno-
histochemical analysis showed a positive result for hormonal receptors 
(Progesterone and/or Estrogen) in almost 74% of cases, endorsing their obvious 
hormonal dependence. The malignancy observed was higher than usual, with 40% 
of operated lesions showing HGD or Invasive Carcinoma in Pathological analysis, 
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so surgical resection should be recommended when an MCN is diagnosed during 
pregnancy. The second trimester seems to be a safe time for intervention with low 
rates of adverse events, but postpartum could be an option too in individualized 
cases (small size, without high risk features and asymptomatic).  
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TABLES 
 
Table 1. Patient demographics and MCNs characteristics  
Author Age Size 
Locatio
n 
Hormonal 
Receptors 
Ovarian-type 
Stroma 
Pathological 
diagnose 
Millastre, 2015 37 8 cm Tail NR ✔ Benign MCN 
Shamali, 2015 23 7 cm Tail NR ✔ Benign MCN 
Antila, 2015 28 8 cm Tail NR ✔ MCN with HGD 
Kosumi, 2015 33 6 cm 
Body-
Tail 
PG(+) ES(+) ✔ Benign MCN 
Takashima, 2014 28 7 cm Head PG(+) ES(+) ✔ MCN with HGD 
Tica, 2013 27 11,6 cm 
Body-
Tail 
(-) ✔ Benign MCN 
Iusco, 2012 28 16 cm Tail PG(+) ES(+) ✔ MCN with IC 
Tsuda, 2012 28 14 cm 
Body-
Tail 
PG(+) ES(+) ✔ MCN with HGD 
Naganuma, 2011 32 11 cm Head PG (+) ✔ MCN with IC 
Shirakawa, 2010 34 19 cm Tail PG(+) ES(+) ✔ MCN 
Brown, 2009 38 10 cm 
Body-
Tail 
NR ✔ 
MCN with HGD 
(R1) 
Hakamada, 2008 38 10 cm Tail PG (+) ✔ 
MCN + Anaplastic 
Carcinoma 
Ikuta, 2008 30 18 cm Tail PG(+) ES(+) ✔ MCN with LGD 
Berindoague, 2007 31 15 cm 
Body-
Tail 
(-) ✔ MCN with IC 
Wiseman, 2007 32 15 cm Tail PG(+) ES(+) ✔ MCN with LGD 
Komatsu, 2007 31 15 cm 
Body-
Tail 
PG(+) ES(+) ✔ MCN with LGD 
Ishikawa, 2007 33 12 cm 
Body-
Tail 
(-) ✔ Benign MCN 
Herring, 2007 34 19 cm 
Body-
Tail 
PG(+) ES(+) ✔ MCN with HGD 
Kitagawa, 2006 25 15 cm Body PG(+) ✔ Benign MCN 
Kato, 2005 33 17 cm 
Body-
Tail 
PG(+) ES(+) ✔ Benign MCN 
Lopez, 2005 26 15 cm 
Body-
Tail 
NR ✔ Benign MCN 
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Table 2. Demographics and MCNs characteristics in patients with Ovarian-type Stoma not 
reported 
Author Age Size Location 
Hormonal 
Receptors 
Ovarian 
Stroma 
Pathological 
diagnose 
Boyd, 2012 21 17,2cm Body NR NR MCN with LGD 
Asciutti, 
2010 
31 8,3 cm Tail NR NR 
Benign MCN 
No communication 
with pancretic ducts 
Ozden, 2007 32 15 cm Tail (-)  NR  
Cystadenocarcinom
a growing inside a 
Mucinous 
cystadenoma 
Yuzefovich, 
2007 
22 15 cm Tail NR NR 
Benign Mucinous 
Cystadenoma 
Matsumago
, 2004 
28 20 cm Tail PG (+) NR 
Mucinous 
Cystadenocarcinom
a  
Olsen, 1993 25 5 cm Tail NR NR Benign MCN 
Baiochi, 
1990 
29 10 cm Tail NR NR 
Cystadenocarcinom
a growing inside a 
Mucinous 
cystoadenoma 
Smithers, 
1986 
33 10 cm Body-Tail NR NR 
Cystadenocarcinom
a of the pancreas 
Ganepola, 
1999 
37 12 cm Body-Tail PG(+) ES(+) NR Benign MCN  
 
 
 
 
  
59 
 
CHAPTER 4 
SUMMARY 
 
Pancreatic mucinous cystic neoplasms (MCNs) have been defined by the World 
Health Organisation from 2000 as well-demarcated cystic lesions, lined by a mucin-
producing columnar epithelium overlying an ovarian-type stroma. Although MCNs 
are classified as neoplastic lesions their actual malignant potential remains 
uncertain, with rates of associated invasive cancer ranging anywhere between 0 and 
34% in the current literature. 
 
The current management of MCNs is defined by a number of consensus guidelines 
from the International Association of Pancreatology (IAP), Europe, and the 
American Gastroenterology Association. The IAP and European guidelines 
specifically mention the management of MCN and both stipulate that where the 
diagnosis is certain and the patient is an operative candidate then surgical resection 
should be performed. Within the European consensus statement on cystic lesions of 
the pancreas, there is a proviso that where the diagnosis is uncertain and there are 
no associated worrisome features and the lesion is less than 4cm, then management 
of a MCN as a branch duct IPMN, with surveillance may be appropriate. 
 
Our comprehensive systematic review supports emerging trends in the literature 
that MCNs are probably more indolent lesions than was previously thought. They 
have a low aggressive behavior, with exceptionally low rates of malignant 
transformation when less than 4cm in size, are asymptomatic and lack worrisome 
features on pre-operative imaging. Conservative management, particularly of small 
MCNs appears to be a reasonable strategy. This differs significantly from the 
natural history of small BD-IPMNs, supporting the need to differentiate mucinous 
cyst subtypes pre-operatively, where possible.  
Our large multicentre cohort concluded that, in female patients, malignancy or 
HGD was solely seen in MCNs with symptoms or worrisome features on 
preoperative imaging, regardless of the size of the tumour. In males, the risk of 
60 
 
malignancy was significantly higher than in females, suggesting that operative 
treatment should be considered in all male patients with a suspected MCN of any 
size. In female patients conservative management seems to be a safe approach for 
suspected MCNs of any size without symptoms or worrisome features. 
Pancreatic MCNs diagnosed during pregnancy are often large and grow rapidly; 
this suggests a strong correlation between this type of lesions and hormones.  
 
These findings support the management of MCN advocated by the recent European 
Guidelines. The conclusion of this thesis should change the management of patients 
with MCNs in many centres worldwide. 
